Clinical Trials Browser

Phase 2 × INDUSTRY × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all

NCT03363373 2026-02-19

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Phase 2 Recruiting

122 enrolled 2 FDA

Neuroblastoma

NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Phase 2 Active not recruiting

Glioblastoma, Gliosarcoma

NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

22 enrolled 8 charts

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01265433 2024-10-09

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

Phase 2 Completed

41 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02297698 2023-12-12

HER3+

Phase 2 Completed

100 enrolled 11 charts

Breast Neoplasms

NCT02978222 2022-12-15

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Phase 2 Terminated

120 enrolled 12 charts

Ovarian Neoplasms

NCT04909515 2022-09-01

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Phase 2 Withdrawn

Neuroblastoma

NCT05366062 2022-05-13

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

Phase 2 Not yet recruiting

Glioma

NCT02873819 2022-03-08

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT00458601 2018-01-16

ACT III

Phase 2 Completed

Glioma

NCT01909752 2017-07-06

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00554372 2016-02-04

A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

Phase 2 Completed

30 enrolled 11 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00969722 2013-03-08

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Phase 2 Terminated

Neuroblastoma